Cohen Capital Management Inc. Raises Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Cohen Capital Management Inc. grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 22.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 10,938 shares of the company’s stock after buying an additional 1,984 shares during the period. Cohen Capital Management Inc.’s holdings in Moderna were worth $455,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in MRNA. State Street Corp raised its stake in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares during the period. Wellington Management Group LLP raised its position in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares during the period. Two Sigma Advisers LP bought a new stake in shares of Moderna during the 3rd quarter valued at $23,825,000. International Assets Investment Management LLC lifted its stake in shares of Moderna by 10,687.1% during the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after buying an additional 316,552 shares in the last quarter. Finally, Douglas Lane & Associates LLC boosted its holdings in Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after buying an additional 298,715 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $35.53 on Friday. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The business’s 50 day moving average is $38.04 and its two-hundred day moving average is $52.66. The stock has a market capitalization of $13.67 billion, a P/E ratio of -3.83 and a beta of 1.59.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on MRNA shares. UBS Group decreased their price target on Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday. Leerink Partners decreased their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th. Berenberg Bank upped their price target on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, January 16th. Evercore ISI set a $50.00 price objective on shares of Moderna in a research report on Friday, February 14th. Finally, Bank of America lowered their target price on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a report on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus price target of $60.63.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.